Instrument Inactif

Communiqués Acacia Pharma Group plc

Actions

ACPH

GB00BYWF9Y76

Communiqués

09/06/22	Scheme of arrangement becoming effective	GL
09/06/22	Scheme of arrangement becoming effective	AQ
07/06/22	Court Sanction of the Scheme of Arrangement	GL
07/06/22	Court Sanction of the Scheme of Arrangement	AQ
20/05/22	Acacia Pharma Results of the Court Meeting and the General Meeting held on 19 May 2022	AQ
20/05/22	Acacia Pharma Results of the Court Meeting and the General Meeting held on 19 May 2022	GL
02/05/22	Publication of Annual Report and Financial Statements for the Year ended 31 December 2021	AQ
29/04/22	Publication of Annual Report and Financial Statements for the Year ended 31 December 2021	GL
27/04/22	Acacia Pharma : Offer by Eagle – Proxy Forms	PU
27/04/22	Acacia Pharma : Offer by Eagle – S.311A Statement	PU
27/04/22	Acacia Pharma : Offer by Eagle – Scheme Document	PU
27/04/22	Publication of Scheme Document	GL
30/03/22	Acacia Pharma to Postpone Publication of its Results for the Full Year 2021, Scheduled on 31 March 2022	AQ
29/03/22	Acacia Pharma : Scheme of Arrangement Information Sheet	PU
28/03/22	Acacia Pharma : Proposed Transaction with Eagle Pharmaceuticals, Inc (Part 2 of 2)	PU
28/03/22	Acacia Pharma : Proposed Transaction with Eagle Pharmaceuticals, Inc. (Part 1 of 2)	PU
28/03/22	Acacia Pharma : proposed Transaction with Eagle Pharmaceuticals, Inc.	PU
28/03/22	Acacia Pharma : proposed Transaction with Eagle Pharmaceuticals PLC	PU
28/03/22	Offer by Eagle Pharmaceuticals, Inc.	GL
23/03/22	Acacia Pharma Announces Chief Financial Officer Gary Gemignani is to Leave the Company	GL
15/03/22	Issue of Shares to Employee Benefit Trust	AQ
21/12/21	Acacia Pharma Issues Ordinary Shares to its Employee Benefit Trust	AQ
16/12/21	Correction: Issue of Shares to Employee Benefit Trust	AQ
14/12/21	Acacia Pharma Announces Successful Completion of BARHEMSYS Post-approval Requirement Study in Patients with Severe Renal Impairment	AQ
13/12/21	Acacia Pharma Announces Successful Completion of BARHEMSYS® Post-approval Requirement Study in Patients with Severe Renal Impairment	AQ